Great advances in the identification of potentialtarget antigens have occurred in the last twenty years, and the main one is theprotein “M-type phospholipase-A2 receptor” (PLA2R) with the circulatinganti-PLA2R antibody, which makes it possible to evaluate the activity andprognosis of this nephropathy. This evidence concerns the gene PLA2R1 and kidney disorder.